In recent years, many antibody therapies for multiple myeloma have been developed. Antibodies against SLAMF7, CD38, B-cell maturation antigen and PD-1 have been developed and clinical trials are currently under way. As of July 2017, antibodies clinically available in Japan for the treatment of multiple myeloma are elotuzumab against SLAMF7 and daratumumab against CD38. Elotuzumab is a humanized IgG1-kappa monoclonal antibody targeting human SLAMF7. SLAMF7 is a cell surface glycoprotein receptor highly expressed on multiple myeloma cells, and it is also expressed on natural killer cells and is critical for natural killer function. Binding of elotuzumab to natural killer cells leads to activation of natural killer cells, resulting in antibody-dependent cellmediated cytotoxicity of elotuzumab-bound multiple myeloma cells, but not complementdependent cytotoxicity. The result of a randomized phase III trial of elotuzumab+lenalidomide+ dexamethasone (ELOQUENT-2) reduced the risk of disease progression/death by 30% vs lenalidomide+dexamethasone in relapse/refractory multiple myeloma. Daratumumab is a human anti-CD38 IgG1-kappa antibody. CD38 is expressed ubiquitously virtually in all tissues that are highly expressed on plasma cells and it represents an attractive target for immunotherapy using monoclonal antibodies. In the phase III CASTOR trial, patients treated with daratumumab+bortezomib+ dexamethasone had a better CR rate and progression-free survival rate compared with bortezomib+dexamethasone-treated patients (29% vs 10%, median progression-free survival: 16.7 vs 7.1 months, respectively). Moreover, in the phase III POLLUX trial, patients treated with daratumumab+ lenalidomide+dexamethasone had a better response and progression-free survival (CRR or better: 55% vs 23%, 30-month progression-free survival: 58% vs 35%), compared with lenalidomide+ dexamethasone-treated patients.
Introduction
Multiple myeloma (MM) is a hematologic malignancy characterized as an incurable disease. However, the long-term outcome has markedly improved in the last decade due to the development of new treatment options. Nonetheless, patients with refractory to both immunomodulatory drugs (IMiDs: thalidomide, lenalidomide, pomalidomide) and proteasome inhibitors (PIs: bortezomib, carfilzomib, ixazomib) have a short overall survival (OS). There are still existing unmet medical needs for these relapse and/or refractory MM patients. The use of monoclonal antibodies may be associated with improvement in clinical outcomes and favorable toxicity profiles for MM patients. In this situation, many monoclonal antibodies being developed for the treatment of MM patients. In this review, the focus will be on elotuzumab (ELO) and daratumumab (DARA), which were approved in 2016 and 2017 in Japan.
Monoclonal antibodies targeting SLAMF7/CS1
SLAMF7/CS1 SLAMF7 is a member of the signaling lymphocyte activating molecule-related family and is a cell surface glycoprotein receptor highly expressed on normal and malignant plasma cells mediated adhesion to bone marrow stromal cells, previously known as cell surface 1, CS1 (1) . This high level of expression of SLAMF7 on myeloma cells appears to be independent of the presence of cytogenetic abnormalities or molecular subgroup by gene expression profiling. SLAMF7 is also expressed on natural killer (NK) cells, NK-like T-cells, CD8+ T-cells, activated monocytes and dendritic cells which also express SLAMF7, although at lower levels than normal plasma cells. SLAMF7 on NK cells acts as an activating receptor via interaction with the signaling intermediary EAT-2.
Elotuzumab
ELO is a humanized IgG1-kappa monoclonal antibody targeting human SLAMF7 (1) . ELO induces NK cell-mediated antibodydependent cellular cytotoxicity (ADCC) but not complementdependent cytotoxicity (CDC) (2) . Interestingly, ELO activates NK cells via binding of the extracellular protein of SLAMF7 and recruitment of the EAT-2 adaptor protein (2) .
In a phase I, dose-escalation trial, 34 patients with a median of four prior lines of therapy were treated with ELO at dose ranging from 0.5 to 20 mg/kg every 2 weeks (3). No patients achieved PR or better, although nine patients achieved stable disease (Table 1) .
In the phase II trial, 73 patients received ELO 10 mg/kg (n = 36) or 20 mg/kg (n = 37) in combination with lenalidomide and dexamethasone (ELd) (4) . The overall response rate (ORR) in the 10 mg/ kg group had a better response compared with the 20 mg/kg group (92% vs 76%). Median progression-free survival (PFS) in the 10 mg/kg group also had better results compared to the 20 mg/kg group (33 vs 25 months) ( Table 1) .
Lonial et al. reported the result of the randomized phase III trial ELOQUENT-2 (5), comparing ELd and Ld. In this study, 321 patients who had received one to three prior lines of therapy (median 2 lines) treated with ELd had a better median PFS (19.4 vs 14.9 months, hazard ratio, HR = 0.70, P < 0.001). The rate of ORR in the ELd group had a better response compared with the Ld group (79% vs 66%; P = 0.001) and rate of very good partial response (VGPR) or better (33% vs 28%) ( Table 1 ). The most common grade 3 or 4 adverse events (AEs) reported in the ELd group and the Ld group were lymphocytopenia (77% vs 49%), neutropenia (34% vs 44%), thrombocytopenia (19% vs 20%) and anemia (19% vs 21%) ( Table 2) . Infusion-related reactions (IRRs) occurred in 10% of patients (n = 33) in the elotuzumab group and were either grade 1 or 2 in 29 patients. In the extended 3-year follow-up of ELOQUENT-2 trial, 27% of progression/death reduction was sustained (HR = 0.73, P = 0.0014). Especially, in patients with longer time from median diagnosis and one prior line of therapy, the risk of disease progression/death was reduced by 53% in the ELd group vs the Ld group (HR = 0.47) (6) . OS analysis demonstrated a trend in favor of ELd (median OS 43.7 vs 39.6 months, HR = 0.77, P = 0.0257). Jakubowiak et al. reported the result of a randomized phase II trial of elotuzumab+bortezomib+dexamethasone (EBd) vs bortezomib + dexamethasone (Bd) . In this study, 77 patients who had received one to three prior lines of therapy (median 1 line) treated with EBd had a better median PFS (9.7 vs 6.9 months, HR = 0.72, P = 0.09). However, there was no difference of ORR between EBd and Bd (66% vs 63%) (7). Dimopoulos et al. reported the result of randomized phase II trial of elotuzumab+pomalidomide+ dexamethasone (EPd) vs Pd. In this study, 117 patients who had received >2 prior lines of therapy (median 3 lines) treated with EPd had a better median PFS (10.3 vs 4.7 months, HR = 0.54, P = 0.0078). ORR was 53% with EPd vs 26% with Pd (odds ratio 3.24, P = 0.0029). VGPR or better was seen in 20% (EPd) vs 9% (Pd) of patients (8) . 
Monoclonal antibodies targeting CD38
CD38 CD38 is a type II single-chain transmembrane glycoprotein of 46 kDa and can function as a dimer on the cytoplasmic side. CD38 has dual functions. Ligation of the CD38 receptor alone induce substantial fluxes of calcium and CD38 catalyzes the synthesis of cyclic adenosine diphosphate ribose (9) . However, CD38 is expressed ubiquitously in virtually all tissues that are highly expressed on plasma cells and it represents an attractive target for immunotherapy using monoclonal antibodies.
Daratumumab
DARA is a human anti-CD38 IgG1-kappa antibody and it kills MM cells via CDC, ADCC, antibody-dependent cellular phagocytosis (ADCP) and apoptosis via cross-linking (10-12). Interestingly, DARA was selected from a panel of 42 human monoclonal antibodies, because only daratumumab was able to induce CDC.
DARA has unknown immunomodulatory effects through reduction of CD38-expressing immunosuppressive regulatory T, regulatory B and myeloid-derived suppressor cells (13) .
Clinical trials with DARA began with a phase I/II doseescalation (GEN501) (14) , in which DARA was administered weekly for 8 weeks at doses ranging from 0.005 to 24 mg/kg. No maximum tolerated dose was identified. In the dose expansion portion of the study, two different DARA doses (8 vs 16 mg/kg) were compared in 72 patients with a median of four prior lines of therapy. The ORR in the 16 mg/kg cohort was 36% vs 10% in the 8 mg/kg cohort (Table 1 ). In the phase II SIRIUS trial, 106 patients with refractory MM with a median of five prior lines of therapy were enrolled (15) . An updated pooled analysis of both monotherapy studies in the patients treated with DARA 16 mg/kg, GEN501 and SIRIUS, showed an ORR of 31.1%, median PFS of 4.0 months and median OS of 20.1 months (16). This ORR included 4.7% complete response (CR) and 8.8% VGPR ( Table 1) . The most common AEs were fatigue, nausea, anemia, back pain, cough, upper respiratory tract infection, thrombocytopenia and neutropenia. Dara has a manageable toxicity profile with 48% IRRs consisting of nasal congestion, cough, allergic rhinitis, throat irritation, dyspnea, chills and nausea.
Palumbo et al. reported the result of interim analysis of a randomized phase III CASTOR trial of Bd as compared with Bd + DARA (DBd) (17) . In this study, 498 patients who had received at least one prior line of therapy (median 2 lines) were enrolled; 251 patients treated with DBd had a better PFS (at 12-month PFS; 60.7% vs 26.9% with median not reached vs 7.2 months; HR = 0.39, P < 0.001). The rate of ORR in the DBd group had a better response compared with the Bd group (82.9% vs 63.2%; P < 0.001), rate of VGPR or better (59.2% vs 29.1%; P < 0.001) and rate of CR or better (19.2% vs 9.0%; P = 0.001) ( Table 1 ). The rates of negative status for minimal residual disease (MRD) (<10 −5 ) were 12% in the DBd group and 5% in the Bd group. Spencer et al. reported updated efficacy and safety data in CASTOR based on longer follow-up. After a median follow-up of 19.4 months, PFS was significantly prolonged with DBd vs Bd (median PFS, 16.7 vs 7.1 months). A higher CR rate was observed with DBd compared with Bd (29% vs 10%) (18) .
The most common grade 3 or 4 AEs reported in the DBd group and the Bd group were thrombocytopenia (45.3% and 32.9%), anemia (14.4% vs 16.0%) and neutropenia (12.8% vs 4.2%). IRRs associated DARA were 45.3%; these IRRs were mostly grade 1 or 2, and the 98.2% of IRRs occurred during the first infusion (Table 2) .
Dimopoulos et al. reported the result of interim analysis of POLLUX trial, a randomized phase III trial of lenalidomide + dexamethasone (Ld) as compared with Ld + DARA (DLd) (19) . In this study, 569 patients who had received at least one prior line of therapy (median 1) were enrolled; 286 patients treated with DLd had a better PFS (at 12-month PFS; 83.2% vs 60.1%, HR = 0.37, P < 0.001). The ORR in the DLd group had a better response compared with the Ld group (92.9% vs 76.4%; P < 0.001), the rate of VGPR or better (75.8% vs 44.2%; P < 0.001) and the rate of CR or better (43.1% vs 19.2%; P = 0.001). Demopoulos et al. reported updated efficacy and safety data of POLLUX on a longer follow-up. After a median follow-up of 32.9 months, PFS was significantly prolonged with DLd vs Ld (30-months PFS, 58% vs 35%). A higher CR rate was observed with DLd compared with Ld (55% vs 23%) (20) ( Table 1 ). The rates of negative status of for MRD (<10 −5 ) were 27% in the DLd group and 5% in the Ld group. The most common grade 3 or 4 AEs reported in the DLd group and the Ld group were neutropenia (51.9% and 37.0%), thrombocytopenia (12.7% vs 13.5%) and anemia (12.4% vs 19.6%) ( Table 2 ). IRRs associated DARA were 47.7%, these IRRs were mostly grade 1 or 2.
Chari et al. reported the result of a phase Ib trial of daratumumab plus pomalidomide and dexamethasone in relapse/refractory MM (RRMM) (21) . In this study, 103 patients received a median range of 4 (1-13) prior therapies, and the median time since diagnosis was 5.1 (0.4-16.0) years. The ORR was 60%, including sCR (8%), CR (9%), VGPR (25%) and PR (18) . Overall, 6% of patients achieved a negative MRD at thresholds of 10 −5 . In doublerefractory patients, ORR was 58%. At a median follow-up of 13.1 months, median PFS and OS were 8.8 and 17.5 months, respectively. The most common (>6%) grade 3 or 4 AEs were neutropenia (77%), anemia (28%), leukopenia (24%) thrombocytopenia (19%), lymphopenia (14%), fatigue (12%), pneumonia (10%), febrile neutropenia (8%) and dyspnea (8%). Mateos et al. reported the result of interim analysis of a randomized phase III trial of ALCYONE, melphalan+prednisone+ bortezomib (MPB) compared with MPB + DARA (D-MPB) (22) . In this study, 706 patients with newly diagnosed MM who were ineligible for stem cell transplantation were enrolled; 350 patients treated with D-MPB had a better PFS (at 18-month PFS; 71.6% vs 50.2%, HR = 0.50, P < 0.001). The rate of ORR in the D-MPB group had a better response compared with the MPB group (90.9% vs 73.9%; P < 0.001), the rate of VGPR or better (71.1% vs 49.7%; P < 0.001) and the rate of CR or better (42.6% vs 24.4%; P < 0.001) ( Table 1 ). The rates of achieving negative status for MRD (<10 (Table 2) .
CD55, CD59 and CD38 expression on MM cells after DARA treatment CD38 expression decreases from diagnosis of MM through subsequent relapses and low expression of CD38 are associated with poor clinical responses. In the patients treated with DARA, pretreatment levels of CD38 expression on MM cells were significantly higher in patients who achieved at least PR compare with patients who did not achieve PR (23) . After the first DARA infusion, CD38 expression was reduced in MM cells in both responding and nonresponding patients. However, CD38 expression levels on MM cells increased again following DARA discontinuation.
The anticomplement receptors CD55 and CD59 levels were significantly increased on MM cells only at the time of progression after DARA treatment (23) . Interestingly, all-trans retinoic acid increased CD38 levels and decreased CD55 and CD59 expression on MM cells from patients who developed daratumumab resistance (24) .
NK cells in daratumumab therapy
Daratumumab induces NK cell depletion due to the fact NK cells express high levels of CD38 on these cell surface. However, the CD38 
The addition of IMiDs on daratumumab refractory MM patients
Gavriatopoulou et al. reported six patients who were refractory to IMiDs before progressing on DARA monotherapy and subsequently treated with the combination of the patient's refractory IMiDs agent and DARA. DARA was continuously treated at the dose of 16 mg/kg monthly. Pomalidomide was added to the four pomalidomide-refractory patients and lenalidomide to the two lenalidomide-refractory patients. Four of six had achieved PR or better and two had stable disease. The combination of IMiDs and CD38 antibody markedly enhanced NK cell, T-cel-mediated anti-myeloma activity and ADCP (26) . Furthermore, IMiDs may enhance the CD38 expression on MM cells leading to increased activity of CD38 antibodies (27) . Although patient size was small, the activity in patients refractory to both IMiDs and daratumumab was significant. These data support potential synergistic effect of IMiDs with daratumumab (26).
Isatuximab
Isatuximab is another chimeric IgG1-kappa anti-CD38 monoclonal antibody that has been undergoing clinical development. Isatuximab elicits anti-MM activity through direct induction of apoptosis, ADCC, ADCP and CDC. Interestingly, isatuximab and its F(ab)'2 fragments were able to directly induce MM cell death, without crosslinking and independent of effector cells, even with p53 mutation (28) . As recently reported by DARA, targeting CD38 by isatuximab can abrogate CD38 high Tregs and relieving the immunosuppressive bone marrow microenvironment (29) . In addition, isatuximab inhibits the ADP-ribosyl cyclase activity of CD38 (30) . Isatuximab at a dose of 10 mg/kg or more than 10 mg/kg has single-agent activity with an ORR of 24.3% in relapse/refractory MM patients with a median of five prior therapies (31).
Martin et al. reported the result of interim analysis of isatuximab combined with Ld (32) . This study aimed to assess the safety of isatuximab in combination with standard doses of Ld in patients with RRMM. Isatuximab was given in two schedules. In dose-escalation cohorts, isatuximab was administered on days 1 and 15 of each cycle at 3, 5 or 10 mg/kg. In QW/Q2W cohort, isatuximab was evaluated at 10 or 20 mg/kg QW during cycle 1 and then Q2W thereafter. In this study, 57 patients who had received at least one prior line of therapy (median five lines) treated with isatuximab combined with Ld. Excluding patients who discontinued before completing at least one cycle of treatment, the rate of ORR was 56% and was similar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q2W cohorts. In 42 evaluated lenalidomide-refractory patients, the ORR was 52%. The overall median PFS was 8.5 months ( Table 1) . The PFS was longer with the QW/Q2W than the Q2W schedule in patients who received isatuximab 10 mg/kg (9.7 vs 5.7 months). The most common all-grade AEs were diarrhea (53%), fatigue (49%), upper respiratory tract infection (40%) and nausea (35%). The most common grade 3 o 4 AEs were pneumonia (9%), fatigue (7%), febrile neutropenia (5%), anaphylactic reaction (5%) and hypokalemia (5%). Isatuximab has a manageable toxicity profile with 48% IRRs of nasal congestion, cough, allergic rhinitis, throat irritation, dyspnea, chills and nausea. IRRs were observed in 32 patients (56%) and IRRs occurred only with the first infusion in 28 of the 32 patients (88%).
Richardson et al. reported the design of the phase III ICARIA-MM study (NCT02990338) which will evaluate isatuximab plus pomalidomide and dexamethasone vs Pom/dex alone in RRMM. The first patient was recruited in January 2017 (33) .
PD-1-blocking antibodies (nivolumab and pembrolizumab)
The binding between PD-1 on T lymphocytes and PD-L1-expressing tumor cells results in the inhibition of T-cell proliferation and an increase in Treg. Plasma cells from MM patients expressed higher level of PD-L1 compared with plasma cells from MGUS patients. And its expression is upregulated in the relapse and/or refractory phase and in patients with residual disease after therapy (34, 35) .
Nivolumab is a human IgG4-kappa antibody against PD-1. In a phase 1b clinical trial of the anti-PD1 monoclonal antibody nivolumab, 27 MM patients were treated with single agent. Stable disease was the best response for 17 (63%) patients, which lasted a median of 11.4 weeks (36). Drug-related AEs reported in MM patients was 52%. Serious AEs reported were pneumonitis, myositis, and increased creatinine phosphokinase occurring in 4% each.
Pembrolizumab is a humanized IgG4-kappa antibody against PD-1. IMiDs, such as lenalidomide and pomalidomide, reduce PD-L1 and PD-1 expression on MM cells and stimulate effector cytotoxic T lymphocytes and NK cells (37) . In the phase II study of pembrolizumab in combination with pomalidomide and dexamethasone, 48 patients with RRMM received 28-day cycles of pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days and dexamethasone 40 mg weekly. Median age was 64 years and high-risk cytogenetic findings were present in 30 (62%) patients. Patients received a median of three lines of prior therapy and 35 (73%) patients were double-refractory to both a proteasome inhibitor and an IMiD. The most common AEs' grades 3-4 were neutropenia (42%), anemia (21%), hyperglycemia (21%), fatigue (15%), pneumonia (15%) and lymphopenia (15%). The most common AEs of autoimmune events were pneumonitis (13%), hypothyroidism (10%), adrenal insufficiency (4%) and hepatitis (4%). The ORR was 60%, including sCR (8%) and VGPR (19%). After a median follow-up of 15.6 months, median PFS was 17.4 months and median OS has not been reached. Median PFS was 15.1 months in the high-risk group and 19 months in the low-risk group. Although this combination therapy has acceptable safety and durable response in RRMM, the US Food and Drug Administration (FDA) is issuing the statement about the risks associated with the use of pembrolizumab in combination with an immunomodulatory agent (lenalidomide or pomalidomide) and dexamethasone for the treatment of MM patients. The FDA statement is based on the data from two clinical trials of KEYNOTE-183 (pembrolizumab, pomalidomide and dexamethasone for RRMM) and KEYNOTE-185 (pembrolizumab, lenalidomide and dexamethasone for NDMM). The FDA required that all patients in these two trials to be discontinued, due to interim results demonstrated on increased risk of death for patients receiving pembrolizumab when combined with lenalidomide or pomalidomide as compared with the control group. 
Bispecific T-cell engager

Conclusion
The efficacy of daratumumab and elotuzumab in patients with RRMM has been demonstrated in phase III clinical trials. Now, treatment options have expanded dramatically; many clinical studies are ongoing with new combination therapies including monoclonal antibodies that have the potential to produce deeper and more durable response for patients in both newly diagnosed and relapsed disease (Table 3 ). These studies are critical when defining the optimal combination of these agents with the highest effectiveness. The future treatment of MM is promising as combinations with monoclonal antibodies and novel agents are utilized in the earlier course of the disease.
